Nearly all patients with inflammatory bowel disease will at some point in their disease process require immunosuppressive therapy to manage their symptoms, such as steroids, purines, thiopurines and biological agents. However, using two or more of these therapies together will increase the risks of the patient developing vaccine-preventable opportunistic infections. In this article, describe s a small, prospective audit, which revealed that as significant proportion of patents were not aware of the vaccinations they required while receiving immunosuppressive therapy and of the need to avoid line vaccines.